Canaccord lowered the firm’s price target on Perrigo (PRGO) to $20 from $40 and keeps a Buy rating on the shares. The firm noted Q3 was a beat but sales were weak in light of OTC trends and lower nutrition sales due to velocities below expectations and lapping a period where infant formula benefited from selling into retailers due to the port strike last year.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRGO: